HIV-specific antibody immunity mediated through NK cells and monocytes
- PMID: 24191935
- DOI: 10.2174/1570162x113116660061
HIV-specific antibody immunity mediated through NK cells and monocytes
Abstract
The partial success of the RV144 trial re-energized the field of HIV vaccine research, which had stalled after vaccines based on neutralizing antibody and cytotoxic T cells had failed to induce protection. A large post-vaccine research effort has focused attention on the role of non-neutralizing antibodies in the protection afforded by the RV144 vaccine. These binding antibodies can initiate immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) and combine elements of the adaptive and innate immune system in the form of antibodies and effector cells (including NK cells, monocytes and granulocytes). A complex interplay exists between the variable portion of the binding antibody and its HIV antigen target on one hand and the constant region of the antibody and the Fcγ-receptor of the effector cell on the other hand. Technical advances have revolutionized the abilities of scientist to detect the targets of non-neutralizing antibodies, including both envelope and non-envelope epitopes, and their role in forcing escape. Our understanding of the antibody characteristics (including IgG subclasses and Fc glycan profile) is providing valuable insights into their optimal structure and function. We expand on critical research on ADCC effector cells, particularly education of NK cells. We introduce the concept of HIV antibodydependent trogocytosis by monocytes as a potentially important aspect of HIV immunity. In summary, this review highlights recent advances in HIV-specific antibody immunity mediated through NK cells and monocytes.
Similar articles
-
Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses.Vaccine. 2013 Nov 12;31(47):5506-17. doi: 10.1016/j.vaccine.2013.08.035. Epub 2013 Aug 24. Vaccine. 2013. PMID: 23981432 Review.
-
Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.Sci Rep. 2017 Oct 4;7(1):12655. doi: 10.1038/s41598-017-12883-6. Sci Rep. 2017. PMID: 28978939 Free PMC article.
-
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells.Front Immunol. 2019 Nov 27;10:2741. doi: 10.3389/fimmu.2019.02741. eCollection 2019. Front Immunol. 2019. PMID: 31827470 Free PMC article. Clinical Trial.
-
Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Curr HIV Res. 2017;15(3):202-215. doi: 10.2174/1570162X15666170320112247. Curr HIV Res. 2017. PMID: 28322167 Free PMC article. Review.
-
Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.Front Immunol. 2019 Dec 18;10:2968. doi: 10.3389/fimmu.2019.02968. eCollection 2019. Front Immunol. 2019. PMID: 31921207 Free PMC article. Review.
Cited by
-
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.J Infect Dis. 2017 Mar 15;215(suppl_3):S152-S159. doi: 10.1093/infdis/jiw555. J Infect Dis. 2017. PMID: 28520963 Free PMC article. Review.
-
Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era.Front Immunol. 2022 May 11;13:886562. doi: 10.3389/fimmu.2022.886562. eCollection 2022. Front Immunol. 2022. PMID: 35634290 Free PMC article. Review.
-
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.Vaccine. 2021 Jun 29;39(29):3879-3891. doi: 10.1016/j.vaccine.2021.05.090. Epub 2021 Jun 4. Vaccine. 2021. PMID: 34099328 Free PMC article. Clinical Trial.
-
Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission.PLoS One. 2016 May 10;11(5):e0154656. doi: 10.1371/journal.pone.0154656. eCollection 2016. PLoS One. 2016. PMID: 27164006 Free PMC article.
-
Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.J Virol. 2018 Nov 12;92(23):e00895-18. doi: 10.1128/JVI.00895-18. Print 2018 Dec 1. J Virol. 2018. PMID: 30209173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical